Core Viewpoint - The stock price of Yuan Da Pharmaceutical (00512) surged over 7% ahead of its earnings announcement, reflecting positive market sentiment driven by recent FDA approval of its radioactive product for treating unresectable hepatocellular carcinoma (HCC) [1] Company Developments - Yuan Da Pharmaceutical plans to hold a board meeting on August 19 to approve its interim results [1] - The company announced that its yttrium-90 microsphere injection has received FDA approval for a new indication, making it the first and only selective internal radiation therapy product approved for both unresectable HCC and colorectal cancer liver metastases [1] - The company has established a complete industrial chain in the nuclear medicine sector, with its core product, Yttrium-90 microsphere injection, rapidly gaining market traction since its domestic approval in 2022 [1] Market Performance - As of the report, Yuan Da Pharmaceutical's stock rose by 6.92%, trading at HKD 8.96, with a transaction volume of HKD 283 million [1] - Tianfeng Securities projected that by the end of 2024, the product will have treated nearly 2,000 patients and is expected to generate nearly 500 million yuan in sales revenue [1] Strategic Focus - The company aims to build a comprehensive layout in tumor interventional therapy and the RDC platform, actively advancing multiple nuclear medicine products in clinical research [1] - The outlook for the company is positive as it enters an accelerated development phase [1]
远大医药尾盘涨超7% 今日盘后将发中期业绩 机构看好公司进入加速发展阶段